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and side effects), and efficacy and safety of AA agents were
obtained from an expert panel of fifteen cardiologists. Unit
costs were estimated from published studies and Medicare
and state reimbursement rates. Expected costs for each
therapy were estimated for patients with and without struc-
tural heart disease (SHD), then weighted by corresponding
estimates of prescription frequencies to obtain expected
costs for a typical patient.
RESULTS: The annual costs of maintaining NSR in pa-
tients with and without SHD ranged from $3,763 (quini-
dine) to $4,749 (amiodarone) and from $2,912 (quinidine)
to $3,773 (sotalol) per patient, respectively. For a typical
patient, the total annual cost of maintaining NSR was
$3,809. Costs of therapy initiation and side effects were es-
timated to be $1,341 and $1,198, respectively; together,
these constituted 67% of total treatment cost. Costs of in-
patient care represented over 64% of total cost.
CONCLUSIONS: The cost of maintaining NSR with
available AA therapies is $3,809 for a typical AF/F patient.
Costs of inpatient therapy initiation and side effects consti-
tute the majority of the total cost. Total treatment costs are
highest for amiodarone and sotalol in patients with and
without SHD, respectively.
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OBJECTIVE: To determine drug costs to establish and
maintain treatment for hypertension with amlodipine and
felodipine.
METHODS: Data from published reports of 4 controlled
trials directly comparing amlodipine and felodipine were
analyzed. Three trials were identified from a comprehen-
sive Medline search; one trial was cited as a reference. For
one study, the unpublished study report supplemented in-
formation from the published report. In all 4 trials, sub-
jects with mild-to-moderate hypertension were started on
5 mg of study drug and titrated to higher dosages after 2
to 8 weeks if hypertension was not controlled. Maximum
dosages of amlodipine and felodipine were 10 mg in 3
studies. One study allowed titration to felodipine 20 mg.
In another study, lisinopril was added if hypertension was
not controlled by monotherapy. Data were pooled across
studies to determine the fraction of patients titrated to
greater than 5 mg or dual therapy. For the cost analysis,
average drug costs to establish and maintain treatment
were calculated from dosages during and at the end of
each trial, respectively. Where published reports did not
indicate timing of withdrawals, upper and lower limits
yielded high and low estimates of cost to establish treat-
ment. Average (US) wholesale prices were used for drug
costs. Statistical significance was assessed with a chi-
square test.
RESULTS: Fewer amlodipine (45%) than felodipine
(55%) patients were titrated to greater than 5 mg or dual
therapy (p  0.013). Average drug costs/patient-day
across the four studies ranged: 
Varying assumptions about timing of withdrawals
changed results by 3-percent or less. Higher costs with
felodipine were found in the study that allowed titration to
felodipine 20 mg.
CONCLUSION: The higher price of amlodipine may be
offset by higher dosages or greater need for dual therapy
with felodipine. Actual drug costs depend on dosages and
combinations used in practice.
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OBJECTIVES: The prevalence of PAD is known to be
underestimated as a large percentage of patients are not
diagnosed. As PAD is a risk marker of atherothrombotic
disease, potential ischemic events (ischemic stroke, myo-
cardial infarction) have to be taken into account while
studying the economic burden of PAD.
METHODS: A hypothetical cohort of 1000 patients with
established PAD was used for studying, on a 2-year fol-
low-up period basis, the average management of PAD pa-
tients with and without complications (amputations, is-
chemic stroke, myocardial infarction). Probabilities of
occurrence of ischemic events came from previous large
clinical trials and were used in a Markov model. The
costing was performed using French data costs.
RESULTS: The average cost of management of a PAD
patient over a two-year period was assessed taking into
account the probability of occurrence of complications
(amputation, ischemic stroke, myocardial infarction)
without any preventive treatment. This cost is almost 3
times higher than the average cost of management of a
PAD patient over a two-year period without any compli-
cations (4501 Euros compared to 1707 Euros).
CONCLUSION: The evaluation of the economic burden
of PAD has to take into account the risk of occurrence of
ischemic events. In these patients, a preventive treatment
with antiplatelet agents can significantly reduce the cost
Amlodipine Felodipine
Establish treatment $1.49–$1.59 $1.17–$1.71
Maintain treatment $1.63–$1.74 $1.28–$1.98
